- Andera Partners, which co-led the company’s $83 million Series A financing in 2021 and supported in the Series B and C rounds, reinvests in its $150 million IPO on NYSE
- The Company’s stock under the ticker EVMN opened at $17.25 at the trading debut and closed at $20.23, up 26.4% from the $16.00 offering price
- This successful IPO in our porfolio follows just weeks after ImCheck’s €1B acquisition by Ipsen and Tubulis’ €344M financing as the largest for a European biotech
Andera Partners today announced that it participated in the $150 million IPO on NYSE of its portfolio company Evommune, demonstrating Andera’s continued support of the company’s value creation through clinical development and pipeline expansion. The Company is now trading under the ticker EVMN. The stock opened on October 16th at $17.25 in the company’s public trading debut and closed at $20.23, up 26.4% from their $16.00 offering price.
The proceeds from the IPO will be used to fund the clinical development of its most advanced clinical-stage product candidate EVO756 (oral MRGPRX2 antagonist) in the Phase 2/3 trials in chronic spontaneous urticaria (CSU) and atopical AD, as well as product candidate EVO301 in the Phase 2 trial of of AD. The remaining proceeds will support pipeline expansion on several early promising programs.
Yuexin Yu, Director at Andera Partners, added: “The Evommune IPO is particularly remarkable given that 2025 has been a quiet biotech IPO year. This important transition allows the company to tap into the public market as it is fast advancing multiple Ph2 studies for EVO756 and EVO301. Evommune is clearly bringing something unique with its class leading oral MRGPRX2 antagonist starting in chronic urticaria and atopic dermatitis and with additional indications to come. Being its major investor since 2021, Andera Partners has accompanied the team led by Luis Pena through each development phase of the company and stays committed to its value creation trajectory.”